ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4373-4380

  Woessner, Richard ^a   Tunquist, Brian ^a   Lemieux, Christine ^a   Chlipala, Elizabeth ^b   Jackinsky, Steve ^b   Dewolf Jr , Walter ^a   Voegtli, Walter ^a   Cox, April ^a   Rana, Sumeet ^a   Lee, Patrice ^a   Walker, Duncan ^a  

^a ARRAY BIOPHARMA INC   (United States)

^b Premier Laboratory   (United States)

Author keywords

ARRY 520; Hematological tumors; KSP inhibitor; Taxane resistant

Indexed keywords

ANTIMITOTIC AGENT; ARRY 520; DOCETAXEL; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MITOSIS INHIBITION; MITOSIS SPINDLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR CELL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; CELL GROWTH PROCESSES; CELL LINEAGE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HCT116 CELLS; HELA CELLS; HL-60 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; K562 CELLS; KINESIN; MICE; MICE, INBRED NOD; MICE, SCID; MITOSIS; NEOPLASMS; TAXOIDS; THIADIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75149121482     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Morris PG and Fornier MN: Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14: 7167-7172, 2008.
2. Sarli V and Giannes A: Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 14: 7583-7587, 2008.
3. Miglarese MR and Carlson RO: Development of new cancer therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15: 1411-1425, 2006.
4. Gerecitano J, O'Connor OA, Van Deventer H et al: A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 administered on days 1 and 15 every 28 days without and with prophylactic G-CSF in non-Hodgkin or Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 112: 1563, 2008.
5. Rodon J, Till E, Patnaik A et al: Phase I study of ispinesib in combination with capecitabine in patients with advanced solid tumors. Eur J Cancer Supp 4: 640, 2006.
6. Jones SF, Plummer ER, Burris HA III et al: Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 24: 2027, 2006.
7. Harrison MR, Holen KD and Liu G: Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7(1): 54-64, 2009.
8. Lemeiux C, DeWolf W, Voegtli W et al: ARRY-520, a novel, highly selective KSP inhibitor with potent anti-proliferative activity. Proc Am Assoc Cancer Res 48: 5590, 2007.
9. Yan Y, Sardana V, Xu B et al: Inhibition of a mitotic protein: where, how, and conformational consequences. J Mol Biol 335: 547-554, 2004.
10. Mehta RR, Bratescu L, Graves JM et al: Human breast carcinoma cell lines: ultrastructural, genotypic, and immunocytochemical characterization. Anticancer Res 12: 683-692, 1992.
11. Woessner R, Tunquist B, Chlipala E et al: ARRY-520, a KSP inhibitor with potent in vitro and in vivo efficacy and pharmacodynamic activity in models of multiple myeloma. Eur J Cancer Supp 6(12): 447, 2008.
12. Lee J-S, Pauli K, Alvarez M et al: Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharm 46: 627-638, 1994.
13. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE and Cowan KH: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986.
14. Scudiero DA, Monks A and Sausville EA: Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 90: 862, 1998.
15. Tsuruo T, Iida-Saito H, Kawabata H, Oh-Hara T, Hamada H and Utakoji T: Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 77: 682-692, 1986.
16. Tunquist B: Degradation of the anti-apoptotic protein mcl-1 correlates with mitotic cell death in response to the novel KSP inhibitor ARRY-520. Proc Am Assoc Cancer Res 50: 3867, 2009.
17. Shi J, Orth JD and Mitchison T: Cell type variation in response to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 68: 3269-3276, 2008.
18. Gasciogne KE and Taylor SS: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14: 111-122, 2008.
19. Blagosklonny MV: Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6: 70-74, 2007.
20. Bekier ME, Fischbach R, Lee J and Taylor WR: Length of mitotic arrest induced by microtubule-stabilizing drugs determines cell death after mitotic exit. Mol Cancer Ther 8(6): 1646-1654, 2009.
21. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
22. Brito DA, Yang Z and Rieder CL: Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J Cell Biol 182: 623-629, 2008.
23. Chin GM and Herbst R: Induction of apoptosis by monstrol, an inhibitor of the mitotic kinesin eg5, is independent of the spindle checkpoint. Mol Cancer Ther 5: 2580-2591, 2006.
24. Brito DA and Rieder CL: Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16: 1194-1200, 2006.
25. Lens SMA, Wolthuis, RMF Klompmaker R et at: Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22: 2934-2947, 2003.
26. Tao W, South VJ, Zhang Y et al: Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 8: 49-59, 2005.
27. Akgul C: Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66(8): 1326-1336, 2009.
28. Akgul C, Moulding DA, White MRH and Edwards SW: In vivo localization and stability of human mcl-1 using green fluorescent protein (GFP) fusion proteins. FEBS Lett 478: 72-76, 2000.
29. Derenne S, Monia B, Dean NM et al: Antisense strategy shows that mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 100: 194-199, 2002.
30. Wuilleme-Toumi S, Robillard N, Gomez P et al: Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19: 1248-1252, 2005.
31. Awan FT, Kay NE, Davis ME et al: Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 113(3): 535-537, 2009.
32. Estrov Z, Cortez J, Borthakur S et al: A phase 1 dose escalation study of the novel KSP inhibitor ARRY-520 in advanced leukemias. J Clin Oncol 27: 7022, 2009.